Miltenyi Biotec, Bergisch Gladback, Germany, has expanded its antibody portfolio and now offers more than 500 new recombinantly engineered antibodies, the ReAfinity antibodies, optimized for flow cytometry. A strictly standardized antibody production process starting from a defined DNA sequence ensures high purity and lot-to-lot consistency. In addition, the recombinant antibodies do not display mixtures of heavy and light immunoglobulin chains. Certain site-specific mutations are introduced into the antibodies to eliminate nonspecific binding of antibodies to Fc receptors, thereby avoiding background signals. Additionally, they all have the same IgG1 isotype. For more information, visit Miltenyi Biotec.